Publications by authors named "Akos Pap"

Claim this Profile
R
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.
Shea Hogan, Michael Szarek, E Sebastian Debus, Mark Nehler, Sonia S Anand, Akos Ferenc Pap

J Am Heart Assoc· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism.
Paul P Dobesh, Albert A Volkl, Ákos Ferenc Pap, C V Damaraju, Bennett Levitan

Drugs Aging· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial.
Christoph Male, Anthonie W A Lensing, Anthony K C Chan, Gili Kenet, Guy Young, Akos F Pap

Lancet Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design.
Angelo Karaboyas, Junhui Zhao, Laszlo B Tanko, Kristian Tore Joergensen, Akos F Pap

J Am Heart Assoc· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches.
John W Eikelboom, Qilong Yi, William F McIntyre, Jacqueline Bosch, Richard Whitlock, Ákos F Pap

Can J Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
Wolfgang C Winkelmayer, Anthonie W A Lensing, Ravi I Thadhani, Kenneth W Mahaffey, Michael Walsh, Ákos F Pap

Kidney Int· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE.
Norikazu Yamada, Weiguo Fu, Zhenyu Shi, Ki-Hyuk Park, Hyo-Soo Kim, Akos F Pap

Thromb J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial.
Jeffrey I Weitz, László B Tankó, Jürgen Floege, Keith A A Fox, Deepak L Bhatt, Ákos F Pap

Nat Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr.
Joseph S Palumbo, Anthonie W A Lensing, Leonardo R Brandão, Hélène L Hooimeijer, Gili Kenet, Akos F Pap

Blood Adv· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants-A substudy of the EINSTEIN-PE study.
Hanke M G Wiegers, Josien van Es, Ákos F Pap, Anthonie W A Lensing, Saskia Middeldorp

J Thromb Haemost· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin.
Kochawan Boonyawat, Anthonie W A Lensing, Martin H Prins, Jan Beyer-Westendorf, Paolo Prandoni, Akos F Pap

Res Pract Thromb Haemost· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
William R Hiatt, Marc P Bonaca, Manesh R Patel, Mark R Nehler, Eike Sebastian Debus, Akos F Pap

Circulation· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).
Philip Connor, Mayte Sánchez van Kammen, Anthonie W A Lensing, Elizabeth Chalmers, Krisztián Kállay, Akos F Pap

Blood Adv· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE).
Katharina Thom, Anthonie W A Lensing, Ildar Nurmeev, Fanny Bajolle, Damien Bonnet, Ákos Ferenc Pap

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Marc P Bonaca, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Mark R Nehler, Akos F Pap

N Engl J Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Christoph Male, Anthonie W A Lensing, Joseph S Palumbo, Riten Kumar, Ildar Nurmeev, Akos F Pap

Lancet Haematol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
Adriaan A Voors, Jeroen J Bax, Adrian F Hernandez, Antonieta B Wirtz, Akos F Pap

Eur J Heart Fail· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Paul Monagle, Anthonie W A Lensing, Kirstin Thelen, Ida Martinelli, Christoph Male, Akos F Pap

Lancet Haematol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.
Sanjiv J Shah, Adriaan A Voors, John J V McMurray, Dalane W Kitzman, Thomas Viethen, Akos Ferenc Pap

JAMA· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study.
Anthonie W A Lensing, Christoph Male, Guy Young, Dagmar Kubitza, Gili Kenet, Ákos F Pap

Thromb J· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Paolo Prandoni, Anthonie W A Lensing, Martin H Prins, Martin Gebel, Akos F Pap

Thromb Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
Martin H Prins, Anthonie W A Lensing, Paolo Prandoni, Philip S Wells, Peter Verhamme, Akos F Pap

Blood Adv· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Jeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, Rupert Bauersachs, Jan Beyer-Westendorf, Akos F Pap

N Engl J Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).
Uwe Zeymer, Thomas Hohlfeld, Jürgen Vom Dahl, Raimund Erbel, Thomas Münzel, Ákos Ferenc Pap

Thromb Haemost· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
Jan Beyer-Westendorf, Anthonie W A Lensing, Roopen Arya, Henri Bounameaux, Alexander T Cohen, Akos F Pap

Thromb Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis